Edwards Lifesciences Corporatio found using ticker (EW) now have 18 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 135 and 97 with a mean TP of 116.78. Given that the stocks previous close was at 88.69 this would imply there is a potential upside of 31.7%. The 50 day MA is 98.71 and the 200 moving average now moves to 107.48. The company has a market cap of $55,212m. Find out more information at: https://www.edwards.com
The potential market cap would be $72,699m based on the market concensus.
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
